ClinicalTrials.gg
Not yet recruitingNCT07525856Updated Oct 22, 2026

Acceptability of a Nurse-led Telehealth Remote Self-monitoring Model of Care in Patients With Rheumatoid Arthritis

An interventional study of Nurse-led telehealth remote self-monitoring in Rheumatoid Arthritis (RA), sponsored by CHU de Quebec-Universite Laval. Not yet recruiting at 4 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by CHU de Quebec-Universite Laval · Not applicable, Interventional, and Other

How we know

Updated Oct 22, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 251 studies in Arthritis, Rheumatoid with a site in Canada — 17 open to participants now, 32 under way, 3 of them phase 3. Arthritis, Rheumatoid · Canada.

Planned enrollment
173rd of 214
104 · median 303
Started
2027
the only one that year
No phase
34 of 251
7 open now
Primary completion
2028-05
later than 24 of 31 live
Registered
250th of 251
by date

Among the 251 studies in Arthritis, Rheumatoid with a site in Canada, this one is the 173rd largest by planned enrollment of the 214 interventional ones that give a count, is the only one that started in 2027, is one of 34 with no phase, reaches primary completion later than 24 of the 31 other live ones, and was the 250th registered.

Arthritis, Rheumatoid

3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

17 of the 251 studies in Arthritis, Rheumatoid with a site in Canada are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 251 studies in Arthritis, Rheumatoid with a site in Canada, or all of them as a file.
02

Study summary

Canada urgently needs new ways to provide rheumatology care that improve treatment and make it easier for people to get high-quality care. E-health technology is a new and promising way to do this, but it hasn't been studied much yet in rheumatology.

The investigators will test a new way to help people with rheumatoid arthritis at four clinics in Quebec. This study will check if the new approach is easy to use, fits well into the clinics' daily routine, and if both patients and healthcare workers find it helpful and acceptable.

This new approach involves nurses helping patients check their own health from home using an online platform.

104 adults who have rheumatoid arthritis and who have had a flare-up or a change in their medication in the last three months, will participate. Some will start using the online self-monitoring tool right away for 16 months, while others will continue with their usual care for 8 months before trying the tool. During the time they use the tool, they will fill out monthly online questionnaires to check their health. A rheumatology nurse will review their answers, suggest any needed care, provide personalized health information, and be available to answer questions through messages.

This new way of care, where nurses help patients monitor their rheumatoid arthritis from home, helps make better use of limited specialist time. It's more convenient for patients, especially those who live far away, and helps meet their needs between regular doctor visits while keeping the quality of care high.

Read the detailed description

Background: Limited access to rheumatologists in Canadian remote regions leads to delays in new-onset rheumatoid arthritis (RA) diagnosis and inadequate follow-up for disease flares or treatment adjustments. There is a critical need for innovative models of care addressing these unmet needs in resource-limited settings. E-health technologies offer a promising solution by bridging the gap between in-person rheumatology appointments. These tools can optimize the use of scarce specialist resources, enhance the continuity and quality of care, and provide greater convenience for patients-particularly in underserved or geographically isolated areas. By supporting timely interventions and patient-centered monitoring, e-health can play a vital role in improving outcomes and ensuring equitable access to care.

Objectives: This study will evaluate the acceptability and feasibility of a nurse-led telehealth remote self-monitoring model of care for patients with RA.

Primary Objective: Acceptability of a nurse-led telehealth remote self-monitoring program, defined as patient-reported perceptions of usefulness, ease of use, attitudes, and overall experience, and assessed with questionnaires and semi-structured interviews.

Secondary Objectives: Feasibility using the RE-AIM implementation framework:

  • Reach: Proportion of eligible patients enrolled and comparison of participant versus non-participant characteristics.
  • Effectiveness: Frequency and relevance of nurse calls, healthcare utilization, health-related quality of life, disease activity, and medication adherence.
  • Adoption: Completion rate of remote monitoring questionnaires, study retention, and reasons for discontinuation.
  • Implementation: Fidelity to protocol, appropriateness of alerts, subsequent actions, and timeliness of in-person visits; identify barriers and facilitators.
  • Maintenance: Intention for continued use among healthcare providers and patients.

Methods - The investigators will recruit 104 adults with RA who experienced a flare or required a DMARDs switch within the preceding three months, from 4 rheumatology practices (community and academic sites) providing care to >15,000 RA patients. All participants will be randomized 1:1 to receive either immediate intervention (for 16 months) or delayed, i.e. usual care for 8 months (control period) followed by 8 months of intervention, consisting of remote self-monitoring using a web platform co-developed with patients, rheumatologists, and nurses. Rheumatology visits will be scheduled every 3-6 months, with additional visits as necessary. The intervention includes nurse-led remote self-monitoring of RA, with patients completing monthly self-assessments of disease activity (RADAI), symptoms and function (PROMIS-29). Rheumatology nurses will receive alerts if monitoring suggests moderate/high disease activity and will contact participants to determine care needed. Tailored information based on PROMIS-29 answers will be sent to facilitate self-management. Asynchronous messaging with rheumatology nurses and information on RA self-management will be available. Data will be collected using questionnaires and semi-structured interviews. Analysis will use quantitative (generalized linear mixed-effect models comparing within group changes [8 months - baseline, both groups combined] and between groups differences [intervention versus control] in continuous variables), and qualitative methods (thematic content analysis by two independent researchers).

Impact and feasibility. A nurse-led remote self-monitoring of RA using a web-based platform codeveloped with patient input, has potential to enhance access to care and more efficiently use scarce rheumatology resources while providing high quality care.

03

Conditions studied

  • Rheumatoid Arthritis (RA)

Keywords

  • Arthritis activity remote self-monitoring
  • Nurse-led telehealth intervention
  • Pilot randomised trial
  • Self-assessment of disease activity
  • RE-AIM implementation framework
  • Semi-structured interviews
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Diagnosis of rheumatoid arthritis (RA) according to the ACR 2010 criteria
  • Disease duration ≥ six months
  • Who experienced a flare defined by an increase of the clinical disease activity index (CDAI) ≥ 4.5 or a DMARDs switch or addition within the preceding three months
  • Understanding French or English

Exclusion criteria

Exclusion Criteria:

  • Inability to consent
  • Inability to complete questionnaires
  • No Internet access
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
104 participants (estimated)

Study arms

  • Experimental
    Immediate intervention (for 16 months)

    The intervention includes nurse-led remote self-monitoring of RA, with patients completing monthly self-assessments of disease activity (RADAI), symptoms and function (PROMIS-29). Rheumatology nurses will receive alerts if monitoring suggests moderate/high disease activity and will contact participants to determine care needed. Tailored information based on PROMIS-29 answers will be sent to facilitate self-management. Asynchronous messaging with rheumatology nurses and information on RA self-management will be available.

    Other: Nurse-led telehealth remote self-monitoring

  • Active comparator
    Delayed intervention ( 8 months of control period followed by 8 months with the intervention)

    Usual care for 8 months, consisting in rheumatology visits scheduled every 3-6 months. Followed by the intervention for 8 months: The intervention includes nurse-led remote self-monitoring of RA, with patients completing monthly self-assessments of disease activity (RADAI), symptoms and function (PROMIS-29). Rheumatology nurses will receive alerts if monitoring suggests moderate/high disease activity and will contact participants to determine care needed. Tailored information based on PROMIS-29 answers will be sent to facilitate self-management. Asynchronous messaging with rheumatology nurses and information on RA self-management will be available.

    Other: Nurse-led telehealth remote self-monitoring

Interventions

  • OtherNurse-led telehealth remote self-monitoring

    Remote self-monitoring will use a web platform co-developed with patients, rheumatologists, and nurses. The intervention includes nurse-led remote self-monitoring of RA, with patients completing monthly self-assessments of disease activity (RADAI), symptoms and function (PROMIS-29). Rheumatology nurses will receive alerts if monitoring suggests moderate/high disease activity and will contact participants to determine care needed. Tailored information based on PROMIS-29 answers will be sent to facilitate self-management. Asynchronous messaging with rheumatology nurses and information on RA self-management will be available.

06

What researchers measure

Primary outcomes

  1. Acceptability of the intervention evaluated by a questionnaire

    The questionnaire of patients' perceived usefulness and ease of use of the remote self-monitoring web platform will be completed by participants at 16 months, rated using a 13-item questionnaire utilizing five-point Likert scales.

    Time frame: At 16 months

  2. Acceptability of the intervention evaluated by a qualitative analysis

    Semi-structured interviews with patients and providers will be completed with a purposive sample of participants (diverse with respect to age, gender, ethnicity, education, disease type and duration, employment, urban/rural) at study end. Participants will meet in groups of 8-12 for 60-90 minutes; groups will continue until saturation of themes is obtained (estimated to be 2-3 groups). Topics will include perceived acceptability, convenience, satisfaction, beliefs, perceived usefulness and ease of use, how care received met patient needs, barriers and enablers to adopting this new model of care.

    Time frame: At 16 months

Secondary outcomes

  1. Age category of eligible participants

    Age category of eligible patients

    Time frame: Until the end of recruiting period

  2. Frequency of calls to nurses

    Frequency of calls to nurses will be collected on the electronic medical record of each rheumatology clinic

    Time frame: Up to the end of intervention at 16 months

  3. Use of other health care services

    Self-reported by patients in a survey administered every three months, including emergency room visits, hospitalizations, visits to primary care physicians, other specialists, other healthcare professionals.

    Time frame: Every 3 months over 16 months

  4. Health-related quality of life evaluated by the Patient-Reported Outcomes Measurement Information System-29 questionnaire

    Measured by the Patient-Reported Outcomes Measurement Information System-29 (PROMIS-29) which is a patient-reported measure of symptoms and function validated in French, which includes four items from each of seven domains (physical function, depression, anxiety, fatigue, sleep disturbances and ability to participate in social roles and activities, pain interference) and a single item on pain intensity. It has been co-developed with patients and validated in rheumatic diseases. Each item has five response options, except for pain which has eleven. A total score is calculated for each domain from the sum of item answers. Range from 20 to 80.

    Time frame: Every 3 months over 16 months

  5. Disease activity evaluated by the Clinical Disease Activity Index

    Measured using Clinical Disease Activity Index (CDAI) at every 3-6 months rheumatology follow-up visit The CDAI is the sum of the count of swollen/tender joint count of 28 joints and patient and physician global assessment on VAS (0-10 cm) Scale for estimating disease activity. The CDAI has range from 0 to 76.

    Time frame: Every 3 to 6 months over 16 months

  6. Proportion of medication adherence

    The proportion of adherence will be calculated by dividing the quantity received by the quantity prescribed for each month starting three months before enrollment until six months after. The mean proportion of adherence per medication will be calculated for each time period by taking the mean of all months included in each of the periods. For each of these periods, the patient will be considered adherent if the mean is greater or equal to 80%.

    Time frame: Every 3 months up to the end of intervention over 16 months

  7. Completion rate of patient questionnaires for remote self-monitoring

    Completion rate of patient questionnaires for remote self-monitoring (Rheumatoid Arthritis Disease Activity Index RADAI and Patient-Reported Outcomes Measurement Information System-29, PROMIS-29)

    Time frame: Every month during the intervention over 16 months

  8. Proportion of participants still connecting to the web platform at study end

    Proportion of participants still connecting to the web platform at study end

    Time frame: At 16 months

  9. Time spent on the web platform

    Time spent on the web platform by each participant

    Time frame: Up to the end of intervention at 16 months

  10. Measuring the number of alerts per patient

    Measuring the number of alerts per patient

    Time frame: Up to the end of intervention at 16 months

  11. Questionnaire for the evaluation of health professionals' acceptance of a new telemonitoring system

    Rheumatology nurses, rheumatologists, and administrative staff will answer the questionnaire for the evaluation of health professionals' acceptance of a new telemonitoring system, a 33-item anonymous survey on their intended sustained use of nurse-led remote self-monitoring with a 7-point likert scale for each questions.

    Time frame: At 16 months

  12. Sex category of eligible patients

    Sex category of eligible patients

    Time frame: Up to the end of recruiting period

  13. Clinical appropriateness of alerts

    Clinical appropriateness of alerts based on rheumatology team subsequent actions (ex: timeliness of in-person visits, whether triggered visits led to medication change)

    Time frame: Up to the end of intervention over 16 months

  14. Number of nurse-patient interactions

    Number of nurse-patient interactions using the platform

    Time frame: Up to the end of intervention over 16 months

  15. Reason for nurse calls

    Reason for nurse calls will be collected on the electronic medical record of each rheumatology clinic

    Time frame: Up to the end of intervention at 16 months

07

Study locations

4 sites
  • Hopital general de Montreal
    Montreal, Quebec H3H 1V6, Canada
    • Ines Colmegna, MD · Contactines.colmegna@mcgill.ca · +1 (514) 934-1934
    • Ines Colmegna, MD · Principal investigator
  • Centre de l'ostéporose et de rhumatologie de Québec
    Québec, Quebec G1V 2M1, Canada
  • CHU de Quebec-Universite Laval
    Québec, Quebec G1V4G2, Canada
  • Hopital Fleurimont et Hotel Dieu de Sherbrooke
    Sherbrooke, Quebec J1H 5H3, Canada
    • Hugues Allard-Chamard, MD · Contacthugues.allard-chamard@usherbrooke.ca · +1 819 821-8000
    • Hugues Allard-Chamard, MD · Principal investigator
    • Javier Marrugo, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for May 2028, 16 months later.

Of 293 non-industry interventional studies with no phase under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 39. This study's planned 16 months is below that.

Counting every sponsor, half of 349 studies reached it within 27 months; a quarter within 13 and three quarters within 47.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: start May 2026 → Jan 2027, primary completion Sep 2027 → May 2028 and completion Dec 2027 → Jun 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2026
First posted
Apr 13, 2026
StartEst.
Jan 2027was May 2026
Primary completionEst.
May 2028was Sep 2027
CompletionEst.
Jun 2028was Dec 2027
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
May 2026→Jan 2027
Oct 22, 2026
Primary completion
Sep 2027→May 2028
Oct 22, 2026
Study completion
Dec 2027→Jun 2028
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Start date May 2026→Jan 2027
    Primary completion Sep 2027→May 2028
    Study completion Dec 2027→Jun 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07525856
Collaborators
The Arthritis Society, Canada
Responsible party
Sponsor
First posted
Apr 13, 2026
Start date
Jan 2027 (estimated)
Primary completion
May 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
Oct 22, 2026

Study contacts

Laetitia Michou, MD PhD
Contact
laetitia.michou@crchudequebec.ulaval.ca
+14185254444 ext. 48383
Laetitia Michou, MD PhD
principal investigator · CHU de Quebec-Universite Laval

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion